Boston Scientific accounts are for healthcare professionals only.
Use co-registration to accurately map an IVUS run to your angiogram image
- No additional contrast or fluoroscopy needed
- Can be initiated at any point in a procedure to confidently navigate complex anatomy
ASA uses artificial intelligence to assess stent placement, minimum stent area, and relative stent expansion
Interested in upgrading?
Contact your Boston Scientific representative to learn more.
Faster workflows. Reliable results.
AI-enhanced workflows
AI-enabled tools like Automated Lesion Assessment (ALA™) and ASA provide consistent workflows for lesion characteristics and stent placement details. ALA demonstrates very strong agreement with both core-lab and interventional cardiologist IVUS assessments (ICC ≥0.99 for lumen measurements) and supports appropriate balloon sizing in >90% of cases.1
AI is transforming intravascular imaging – not by replacing expertise, but by elevating it.
Smarter, real-time visualization
ONPATH software features IVUSCONNECT Co-registration, harnessing AI to simplify orientation, improve anatomical mapping, and provide actionable guidance – without requiring additional contrast or fluoroscopy.
Time-saving efficiencies
By automating repetitive or manual measurement steps, ALA has been shown to reduce analysis time by nearly 60%, supporting a more efficient workflow without sacrificing speed or accuracy.2
Save more time with faster pullback speeds, up to 8 mm/s, for quicker vessel imaging.
Frequently asked questions
ONPATH software expands the AVVIGO+ System with additional AI-enabled tools, including:
- Automated Stent Assessment (ASA): AI-powered post-PCI workflow for stent visualization, placement, minimum stent area, and expansion assessment.
- IVUSCONNECT™ Co-registration: Maps IVUS runs to angiogram images with minimal contrast, aiding navigation of complex anatomy.
ONPATH Software was developed for the AVVIGO+ Multi-Modality Guidance System. This platform is compatible with OPTICROSS imaging catheters. Contact your Boston Scientific representative for ordering and upgrade options.
Yes. Both ACC and ESC guidelines recognize IVUS as a Class 1A recommendation for PCI in complex coronary lesions—reinforcing its role as a best practice for improving procedural outcomes and reducing complications.
A large body of evidence from across RCTs supports optimization of PCI procedures using IVUS-based decision making.3-6 With HD IVUS and adequate calcium preparation, patients will receive the safest and must durable outcomes. Learn more about the clinical evidence supporting IVUS in PCI.
IVUS has demonstrated benefits across a wide range of clinical scenarios, including:
- Complex coronary lesions in the RENOVATE COMPLEX trial3
- Long lesions (>28 mm), as shown in the IVUS-XPL trial4
- Acute coronary syndrome (ACS), with lower event rates in the IVUS-ACS trial5
- Real-world, all-comer populations in the ULTIMATE trial6
This breadth of evidence reinforces IVUS as a versatile tool across lesion types and in complex PCI cases.
ONPATH software transforms traditionally manual, time-intensive IVUS analysis into a streamlined, automated process. AI-powered tools can reduce analysis time by nearly 60%, enabling faster workflows while maintaining objective, reproducible assessments.2 Review these workflow instructional videos.
IVUS enables objective optimization using measurable criteria. Optimal IVUS-guided PCI is associated with significantly lower target vessel failure rates when key criteria are achieved, including:
- Adequate minimum stent area
- Proper stent expansion relative to reference vessel
- Absence of significant edge dissections7
Contact your Boston Scientific representative to discuss purchasing and delivery timelines.
Contact your Boston Scientific representative to learn about purchasing options available to you.
Learn more about how your institution may benefit from ExpertCare™ Equipment Support and Services program participation.
Boston Scientific provides a comprehensive ecosystem of support, including:
- Clinical evidence and data resources
- Training programs and EDUCARE learning platforms
- Workflow guidance and procedural videos
These resources help clinicians and cath lab teams confidently integrate IVUS into routine practice. Learn more.
No, ONPATH software is designed to work with the more advanced imaging capabilities of the AVVIGO+ system. If you would like to explore those capabilites, visit the AVVIGO+ Multi-Modality Guidance System page.
Resources & training
IVUS Guidance Elevates Coronary Outcomes
AVVIGO+ Multi-Modality Guidance System
Interested in upgrading?
Contact your Boston Scientific representative to learn more.
1. Matsumura M, Mintz GS, Dohi T, et al. Accuracy of IVUS-based machine learning segmentation assessment of coronary artery vessel and lumen dimensions and balloon sizing. J Am Coll Cardiol. 2023;81:(8_Supplement) 1353. doi.org/10.1016/S0735-1097(23)01797-7.
2. Rubio PM, Garcia-Garcia HM, Galo J, et al. Artificial intelligence-powered software outperforms interventional cardiologists in assessment of IVUS-based stent optimization. Cardiovasc Revasc Med. 2025;ISSN 1553-8389, https://doi.org/10.1016/j.carrev.2025.07.011.
3. Hong S, Kim B, Shin D, et al. Effect of Intravascular Ultrasound–Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation. The IVUS-XPL Randomized Clinical Trial. JAMA. 2015;314(20):2155-2163. doi:10.1001/jama.2015.15454.
4. Zhang J, Gao X, Kan J, et al. Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial. J Am Coll Cardiol. 2018 Dec 18;72(24):3126-3137. doi: 10.1016/j.jacc.2018.09.013. Epub 2018 Sep 24.
5. Lee JM, Choi KH, Lee JY, et al. Intravascular Imaging-Guided or Angiography-Guided Complex PCI. N Engl J Med. 2023;388:1668-79. doi:10.1056/NEJMoa2216607.
6. Li X, Ge Z, Kan J, et al. Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial. Lancet. 2024;403(10439):1855-1865. doi:10.1016/S0140-6736(24)00282-4.
7. Gao X-F, Ge Z, Kong X-Q, et al. 3-year outcomes of the ULTIMATE trial comparing intravascular ultrasound versus angiography-guided drug-eluting stent implantation. JACC Cardiovasc Interv. 2021;14:247–257. doi.org/10.1016/j.jcin.2020.10.001.